|
Survival Rate of Cervical Cancer Patients According to the 2018 FIGO Staging System: A tertiary hospital based study, Vajira Hospital, Bangkok |
|---|---|
| รหัสดีโอไอ | |
| Creator | Pantana Bangsomboon |
| Title | Survival Rate of Cervical Cancer Patients According to the 2018 FIGO Staging System: A tertiary hospital based study, Vajira Hospital, Bangkok |
| Contributor | Thannaporn Kittisiam, Woraphot Chaowawanit |
| Publisher | PIMDEE Co., Ltd. |
| Publication Year | 2565 |
| Journal Title | Thai Journal of Obstetrics and Gynaecology |
| Journal Vol. | 30 |
| Journal No. | 1 |
| Page no. | 60-67 |
| Keyword | FIGO 2018 staging, validation, cancer, cervix, survival rate |
| URL Website | https://tci-thaijo.org/index.php/tjog/index |
| Website title | www.tci-thaijo.org |
| ISSN | 2673-0871 |
| Abstract | Objectives: To validate survival rate of cervical cancer patients based on the revised 2018 InternationalFederation of Gynecology and Obstetrics (FIGO) staging system.Materials and Methods: Medical records of cervical cancer patients from 2006-2015 were reviewed.The locally-advanced patients without radiological imaging or incomplete medical records wereexcluded. All included patients were assigned as FIGO 2018 staging criteria.Results: Of the 226 patients with cervical cancer analyzed. Mean age was 51 ?12 years (17-90years). Squamous cell carcinoma was the most common cell type in 159 patients (70.4%).According to FIGO 2018 staging criteria, 81 patients (35.8%) were upstaged. The 5-yearprogression-free survival (PFS) of stage IB1, IB2 and IB3 were 83.3%, 90.0% and 84.2%,respectively and the 5-year overall survivals (OS) were 71.4%, 92.2% and 62.5%, respectively.The PFS and OS were not different among 3 sub-stages. The 5-year PFS of stage IIIB, IIIC1and IIIC2 were 68.6%, 89.3% and 62.5%, respectively and the 5-year OS were 71.4%, 92.2%and 62.5%, respectively. The PFS and OS of stage IIIB and IIIC2 were not significantly different(p = 0.163 and 0.166, respectively) while survival of stage IIIC1 was significantly higher thanstage IIIB (p = 0.025 and 0.017, respectively) and IIIC1 (p = 0.001 and 0.001, respectively).Conclusion: The revised 2018 FIGO staging system for cervical cancer was useful to distinguishsurvival rates of patients with locally-advanced disease and distant metastasis while the survivalrate of sub-stages of early-stage disease was no different. Stage III disease, para-aorticmetastasis was the most impact on the survival rate. |
